Phenylephrine for Priapism

Phenylephrine priapism rescue injection is a compounded, preservative-free sterile solution of phenylephrine hydrochloride, prepared in a 1 mL single-dose vial for injection into the corpus cavernosum — the spongy erectile chamber inside the penis. A urologist prescribes it as a rescue dose for an erection that will not go down, a condition called priapism.

It is most often dispensed to men who already use intracavernosal injection therapy for erectile dysfunction, as one part of a plan their prescriber has set up and trained them on. It is not a treatment for erectile dysfunction itself, and it is not something to start on your own.

How does it work?

Phenylephrine is a selective alpha-1 adrenergic agonist. Injected into the corpus cavernosum, it makes the cavernosal smooth muscle and the small arteries there contract. That constriction lets the trapped, deoxygenated blood drain out of the erectile chambers and allows an ischemic erection to come down.

Phenylephrine acts almost entirely on alpha-1 receptors and has very little effect on beta receptors, which is why it is the sympathomimetic generally chosen for this use rather than agents with more direct cardiac stimulation. It can still raise blood pressure and slow the heart rate, which is why blood pressure and pulse are monitored during administration (AUA/SMSNA, Acute Ischemic Priapism).

What is it used for?

Intracavernosal phenylephrine is used to reverse ischemic priapism. The AUA/SMSNA guideline recommends that clinicians manage acute ischemic priapism with intracavernosal phenylephrine together with corporal aspiration, with or without irrigation, as first-line therapy and before operative interventions. That is a Moderate Recommendation at Evidence Level Grade C. Separately, for a prolonged erection of four hours or less that follows intracavernosal injection therapy for erectile dysfunction, the guideline says clinicians should give intracavernosal phenylephrine as the initial treatment option — a statement graded as Expert Opinion. The guideline also sets out, as a Clinical Principle, that clinicians should monitor blood pressure and heart rate in patients receiving intracavernosal phenylephrine (AUA/SMSNA, Acute Ischemic Priapism).

Some urologists give a patient who uses intracavernosal injection therapy — Trimix, Bimix, Quadmix, or alprostadil — a rescue dose to keep on hand as part of a supervised plan. Whether that is appropriate is entirely the prescriber's decision. Your prescriber decides whether you are a candidate, sets the concentration and the dose, trains you or your partner on how and when to use it, and tells you what to do afterward. A rescue dose does not replace emergency evaluation: the standard of care is aspiration and irrigation alongside the injection, performed by a clinician who can monitor you. Bayview Pharmacy does not provide consultations, does not determine appropriateness, and cannot advise you on when to use a rescue dose. A valid prescription is required.

What does the evidence show?

The evidence behind intracavernosal phenylephrine is best described as strong clinical consensus resting on modest formal evidence. The AUA/SMSNA first-line recommendation carries Evidence Level Grade C, meaning it rests largely on observational studies and expert consensus rather than randomized trials, and the guideline's suggested dosing range of 100 to 500 mcg diluted in 1 mL of saline is expert opinion rather than a trial-derived figure.

Reported outcomes are meaningful but incomplete. Diluted phenylephrine injections alone reverse ischemic priapism in roughly 58% of cases, rising to about 81% to 86% when combined with aspiration and irrigation and used within the first 24 to 36 hours after onset (StatPearls, Priapism). Two things follow from that. First, the drug works best as part of a procedure, not by itself. Second, and most importantly, this evidence describes clinician-administered treatment in a monitored setting. There is no comparable body of evidence for patients self-administering phenylephrine at home, and nothing here should be read as showing that a home rescue dose is a safe substitute for emergency care.

How do the presentations compare?

Bayview compounds phenylephrine in several unrelated presentations. Only the 1 mL preservative-free single-dose vial is the priapism-rescue product; the others are separate preparations that happen to share the same ingredient and are never injected.

Presentations are listed for education only. Your prescriber selects the product, concentration, and dose. Never inject a product that was not dispensed for injection.

How is it used?

Use it only exactly as your urologist has directed, and only if they have specifically prescribed and trained you on a home rescue dose. In a clinical setting, phenylephrine is diluted and given as small intracavernosal injections of about 100 to 500 mcg, repeated at roughly five-minute intervals while blood pressure and pulse are checked, usually alongside aspiration and irrigation of the erectile chambers, and stopped if blood pressure changes appear or if the erection persists past about an hour of repeated attempts.

If you have been given a rescue dose to keep at home, follow your prescriber's written instructions on the amount to draw up, where to inject, and how long to wait. Call your urologist or go to an emergency department if the erection has lasted more than four hours, or if it does not fully resolve after the dose your prescriber authorized. Do not repeat doses beyond what you were told. The vial is single-dose: use it once and discard it. A Bayview pharmacist is available for questions about your prescription, but cannot tell you whether or when to use it.

Side effects & safety

Because phenylephrine constricts blood vessels throughout the body, the main risks are cardiovascular. Reported effects include a rise in blood pressure, reflex slowing of the heart (bradycardia), headache, dizziness, palpitations, and irregular heart rhythms. Blood pressure and pulse monitoring during administration is advised for exactly this reason (StatPearls, Penile Irrigation, Aspiration, and Vasoactive Injections). The FDA-approved intravenous phenylephrine labeling notes that its pressor effect can precipitate angina in people with severe arteriosclerosis or a history of angina and can worsen underlying heart failure, and that the pressor effect is increased in people taking monoamine oxidase (MAO) inhibitors (FDA prescribing information). Extra caution is needed with cardiovascular disease, uncontrolled hypertension, and MAO inhibitors.

There are also injection-site risks. Bruising and bleeding into the penis (hematoma) can follow puncture of the tunica albuginea, and repeated injections over time can cause scarring and fibrosis of the erectile tissue. Pain and swelling at the site are common.

If you have more than one episode of priapism, tell your urologist. Repeated episodes are a signal that the intracavernosal injection regimen itself needs to be reassessed — the dose lowered, the formula changed, or the therapy reconsidered — rather than managed with more rescue doses.

Who should not use it?

This is not appropriate for everyone. It should not be used by anyone with a known allergy to phenylephrine or to any component of the preparation. It requires careful evaluation, and in many cases avoidance, in people with significant cardiovascular disease, coronary artery disease or angina, heart failure, arrhythmias, or uncontrolled high blood pressure, and in anyone taking an MAO inhibitor. It is not intended for anyone who has not been prescribed and trained on it by their own prescriber.

Priapism also has causes — sickle cell disease and other blood disorders among them — that need a different workup and different treatment, which is another reason emergency evaluation matters. Tell your prescriber your full health history, allergies, and every medication and supplement you take, so they can decide whether this is appropriate for you.

How should it be stored?

Store the vial in the refrigerator and protect it from light, exactly as your label directs. Keep it in its carton, tightly closed, and out of the reach of children and pets. Do not freeze it. It is a single-dose vial with no preservative: use it once and discard the vial and any remaining solution, even if some is left. Do not use it if the solution is discolored or contains particles, and do not use it after its beyond-use date. Dispose of the vial and needle in a sharps container as your pharmacist directs, and never share it with anyone.

Why is this compounded?

Phenylephrine injection is FDA-approved, but only as an intravenous product for raising blood pressure — for clinically important hypotension in the setting of anesthesia, and for septic shock — supplied as a 10 mg/mL concentrate that must be diluted or as a 100 mcg/mL solution for intravenous bolus (FDA prescribing information). Neither the intracavernosal route nor a small preservative-free single-dose vial at the concentration used for priapism is an FDA-approved presentation, so the route here is off-label and the preparation itself is compounded.

Compounding lets a licensed pharmacy prepare phenylephrine preservative-free, at the exact concentration the urologist specifies, ready to draw up. That matters in an emergency: the AUA guideline notes that having phenylephrine premixed by the pharmacy helps minimize dilution and calculation errors at the moment of use. As a 503A compounding pharmacy, Bayview Pharmacy prepares each order as a sterile preparation in small batches under USP <797> standards. Compounded preparations are not FDA-approved.